Integrating the Science of Addiction and the Science of Wellbeing

Gilley, Elizabeth

doi:10.4172/2329-6488.1000275

Cited by 5 publications

(6 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This RDS family is activity engaged in creating wellbeing (Gilley, 2017), and have made remarkable progress to foster healthy environments for their children (Felitti, Anda, Nordenberg, Williamson, Spitz, Edwards, et al 1998). Genetic Addiction Risk Severity (GARS) testing has given them an advantage other families to not have.…”

Section: Discussionmentioning

confidence: 99%

Stopping Addiction Before It Begins: The Future is now

Gilley¹

2022

JAAR

View full text Add to dashboard Cite

Genetic Addiction Risk Severity (GARS) (Blum et al, 2014; Blum, Badgaiyan, Agan, Frantantonio, Simpatico, et al. 2015; Blum, Baron, Lott, Ponce, Siwicki, et al. 2019) screens for Reward Deficiency Syndrome (RDS) predisposition risk, for polymorphic variance within eleven alleles of the ten most common genes, in mental disorder. The RDS paradigm shift is concerned with treating the underlying neurogenetic and epigenetic challenges of dopaminergic dysfunction, as well as dysfunction in other neurotransmitter channels (Blum, Baron, McLaughlin, & Gold, 2020). Cutting edge psychiatric genomics recognizes that RDS is one preexisting causal influence for addiction (Tsermpini, Adla, & Patrinos, 2022). Consideration of preexisting neurogenetic challenges which affect low dopamine availability or epigenetic insults are not addressed in traditional old school, Minnesota Model twelve steps treatment modalities (Gilley, 2020), nor it is addressed in the current DSM 5th Edition (APA, 2013) (Gondre-Lewis, Bassey, & Blum, 2020). Scientists in the know are hopeful that RDS will be included in the next edition of the Diagnostic and Statistical Manual of Mental Disorders, as exponential increases in research studies from interactive sciences such as psychology, neurology, genetics and epigenetics have greatly enlarged perspective (Mancheno, Navas-Leon, Fernandez-Calderon, Gutierrez, Sanchez-Garcia, et al 2021). Sometimes progress is slow in funneling progressive cutting-edge applications from the research world into the practitioner world (CASA Columbia, 2012). Unfortunately, it is the patients who suffer, as the opioid overdose deaths of more than 100,000 this year alone, attest (Gupta, Bowirrat, Llanos Gomez, Baron, Elman, Giordano, et al 2022; Blum, Fried, Madigan, Giordano, Modestino, Steinbergy, et al 2017; Moran, Blum, Valdez Ponce, Lott, Gondre-Lewis, Badgaiyan, 2021). Not only have there been advancements in treatment models, from the Minnesota Model of the 1950’s, the Harm Reduction Model of the 1980’s (Paquette, Daughters, & Witkiewitz, 2022) and the Neurodevelopmental Model of addiction of the 2000’s (Leyton, 2012, 2014), there have been advancements in unifying theory. The evolution of the history of addiction recovery treatment would never be complete without mentioning the foundational dopamine depletion hypothesis (Dackis, & Gold, 1985; Diani, 2011; Volkow, Fowler, & Wang, 2002), which led to way to the current leading theory of Reward Deficiency Syndrome, which includes consideration of genetic (Dick, & Agrawal, 2008; Uhl, Liu, Walter, Hess, & Naiman, 2002) and epigenetic causal influences (Edwards, Roy, Boyett, Badgaiyan, Thanos, Baron, et al 2020; Vaillancourt, Ernst, Mash, & Turecki, 2017). RDS unifies all addictions, both substance and non-substance under a common rubric (Blum, Bowirrat, Braverman, Baron, Cadet, Kasmi, et al (2021). The Reward Deficiency Syndrome paradigm shift takes into consideration, underlying genetic, biological, physiological, and neurological mechanisms of the brain reward cascade (BRC). In this genomic era of addiction medicine, the new standard of excellence in addiction treatment begins genetic screening (Gilley, 2022 a, b, c). RDS treatment plans are built upon the foundational genetic and epigenetic causal influences (Gilley, 2021, b, c). RDS-Solution Focused Brief Intervention (RDS-SFBI) administers bio-neuro-psychological therapy which assists the client in achieving dopamine homeostasis (Gilley, 2019). Since RDS effects the individual over the entire lifespan, it should be treated as a front-line modality (Blum, Raza, Schultz, Jalali, Green, Brewer, et al 2021), by primary physicians, and teams of RDS specialists (Gilley, Bowirrat, Gupta, Giordano, Dennen, Braverman, Badgaiyan, McLaughin, Baron, & Blum, 2022).

show abstract

Section: Discussionmentioning

confidence: 99%

Stopping Addiction Before It Begins: The Future is now

Gilley¹

2022

JAAR

View full text Add to dashboard Cite

show abstract

“…Biomarkers of molecular and cellular initiation of relapse and/or recovery are being established. Electromagnetic frequency research and application of new neurological-psychological therapies are on the horizon [7]. With all the radiance of hope, addiction science, and the practice of addiction recovery treatment will realign with research, integrating Reward Deficiency Syndrome into its perspective, to re-conceptualize addiction.…”

Section: Discussionmentioning

confidence: 99%

“…Participation in evidence-based integrative mind-body-spirit wellness applications, such as prayer, yoga, meditation, go-gong, tai chi, music, dance, exercise, art, drumming, singing, charitable action, etc. are all associated with increased wellbeing and recovery [7,[24][25][26]. Energy follows focus.…”

Section: Research Reviewmentioning

confidence: 99%

“…Over fifty years of addiction science and neuro-genetic research have identified a new phenotype for impulsive, compulsive, obsessive and addictive behavioral expression which is changing the recovery landscape by linking all addictions under a common rubric [6][7][8][9][10][11][12][13]. The science of Reward Deficiency Syndrome (RDS) offers hope for SUD and for all obsessive, compulsive, and addictive behavioral patterns.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Reconceptualizing Addiction: Integrating the Sciences of Addiction & Reward Deficiency Syndrome, Part 1

2020

JAR

View full text Add to dashboard Cite

Analytic review of research study results from psychology, addiction science, and interactive sciences like neurology, genetics, and epigenetics, implore psychology, psychiatry and addiction recovery treatment fields to enlarge their perspective, by considering underlying causal influence. The appropriate time to re-conceptualize addiction for the practitioner world is now! Treatment protocol must expand beyond mitigation of the symptoms and address genetic, epigenetic and neurological causal influence. The science of Reward Deficiency Syndrome (RDS), offers a new phenotype for addiction, providing a common rubric for all obsessive, compulsive, and addictive behavioral patterns, and contributes understanding of the psychiatric genetics and/or causal influence of dopaminergic dysfunction in other co-occurring mental disorders. In consideration and review of the body of scientific knowledge, to successfully bridge the gap between science and practice, an integration of the sciences of addiction, and Reward Deficiency Syndrome must be achieved [1].

show abstract

“…Humanity is indebted to Dr. Kenneth Blum and his many research colleagues and associates for changing the recovery landscape [14] providing enlarged perspective [15], and current RDSS focused application. [16], the author has evaluated the problems facing the Addiction Treatment Industry; integrated and synthesized new theory in The Evolution of Addiction Treatment: The Disease is RDS and Addiction is its symptom [13]; as well as relayed extended RDS causal influence theory to co-occurring mental illnesses, which are linked by dopaminergic dysfunction, in The New Science of Attention Deficit Hyperactivity Disorder: News from the cutting edge of research science [17]. These dopaminergic dysfunction diseases also include: Obsessive Compulsive Disorder (OCD), Impulse Control Disorders, Behavioral Addictions, Depression [18], the Autism Spectrum, Gilles de la Tourette Syndrome [7], and Parkinson's Disease [19].…”

Section: Introductionmentioning

confidence: 99%

Reward Deficiency Syndrome Solution Focused Brief Therapy to Begin Integrating the Sciences of Addiction & Reward Deficiency Syndrome (RDS)

Gilley¹

2019

J Reward Defic Syndr Addict Sci

View full text Add to dashboard Cite

Reward Deficiency Syndrome Solution Focused Brief Therapy (RDS-SFBT), provided in both individual and group therapy formats, in the practice of Addiction Recovery Treatment, will help the client understand the importance of the challenge to achieve dopamine homeostasis in the recovery process. RDS-SFBT introduces new Reward Deficiency Syndrome concepts and solutions to the practitioner-client world, helping to bridge the gap between the worlds of research and therapeutic practice [1]. Newly created RDS-SFBT will bring awareness of the advancements of cutting-edge global Reward Deficiency Syndrome research efforts [2], and expands the resource application available to the consumer.

show abstract

Integrating the Science of Addiction and the Science of Wellbeing

Cited by 5 publications

References 61 publications

Stopping Addiction Before It Begins: The Future is now

Stopping Addiction Before It Begins: The Future is now

Reconceptualizing Addiction: Integrating the Sciences of Addiction & Reward Deficiency Syndrome, Part 1

Reward Deficiency Syndrome Solution Focused Brief Therapy to Begin Integrating the Sciences of Addiction & Reward Deficiency Syndrome (RDS)

Contact Info

Product

Resources

About